Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Splenic Nerve Stimulation in RA
NCT05003310Recruiting
- Sponsor
- Galvani Bioelectronics
- Start
- Oct 2021
- Primary completion
- Jul 2027
- Countries
- 2
01
Overview
Randomised, single-blind trial (2 arms), sponsored by Galvani Bioelectronics. Primary endpoints: Incidence of Adverse Events at 12 weeks and Incidence of Treatment-Emergent Adverse Events at 24 weeks. Started Oct 2021; status: recruiting.
Beyond the preview
Go deeper on NCT05003310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003310.